SEC Form 4 · accession 0000905718-19-000110
Matinas BioPharma Holdings, Inc. · MTNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jerome D Jabbour
Officer — President and CEO · Director
Period of report
Feb 11, 2019
Accepted (ET)
Feb 13, 2019 · 6:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582554
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $1.08 | Feb 11, 2019 | A | 750,000 | A | — | Feb 10, 2029 | Common Stock | 750,000 | 750,000 | D |
Explanation of responses
- F1The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 11, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.